newsfilter
← Latest News
GlobeNewswire·

Arvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's Disease

NEW HAVEN, Conn., June 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has recently joined the